within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX18_Linsidomine;

model Linsidomine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.6666666666666667e-05,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.04,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.06,
    k12 = 2.2222222222222223e-05,
    k21 = 2.2222222222222223e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Linsidomine</td></tr><tr><td>ATC code:</td><td>C01DX18</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>60</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Linsidomine, also known as SIN-1, is a vasodilator and a prodrug that releases nitric oxide (NO) upon metabolism. It was developed for the treatment of angina pectoris and other cardiovascular conditions due to its ability to induce vasodilation. Linsidomine is not widely used today and is not an approved drug in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for intravenous administration in healthy adult volunteers, as direct PK parameter publications for linsidomine are not available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01DX18 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Linsidomine;
